Head to Head Contrast: Biofrontera (NASDAQ:BFRI) vs. NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation & Earnings

This table compares NRx Pharmaceuticals and Biofrontera”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23 million	86.27	-$28.62 million	($0.55)	-4.42
Biofrontera	$41.71 million	0.33	-$10.54 million	($0.45)	-2.04

Biofrontera has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NRx Pharmaceuticals and Biofrontera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Biofrontera	-13.78%	-145.81%	-31.30%

Volatility and Risk

NRx Pharmaceuticals has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for NRx Pharmaceuticals and Biofrontera, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2	0	6	0	2.50
Biofrontera	1	1	1	0	2.00

NRx Pharmaceuticals presently has a consensus target price of $34.50, indicating a potential upside of 1,319.17%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Biofrontera.

Institutional & Insider Ownership

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 4.9% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Biofrontera beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset. NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.

About Biofrontera

Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.